Kim Emily Y, Vavere Amy L, Snyder Scott E, Chiang Jason, Li Yimei, Patni Tushar, Qaddoumi Ibrahim, Merchant Thomas E, Robinson Giles W, Holtrop Joseph L, Shulkin Barry L, Bag Asim K
Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Neurooncol Adv. 2024 Apr 5;6(1):vdae056. doi: 10.1093/noajnl/vdae056. eCollection 2024 Jan-Dec.
[C]-Methionine positron emission tomography (PET; [C]-MET-PET) is principally used for the evaluation of brain tumors in adults. Although amino acid PET tracers are more commonly used in the evaluation of pediatric brain tumors, data on [C]-MET-PET imaging of pediatric low-grade gliomas (pLGG) is scarce. This study aimed to investigate the roles of [C]-MET-PET in the evaluation of pLGGs.
Eighteen patients with newly diagnosed pLGG and 26 previously treated pLGG patients underwent [C]-MET-PET met the inclusion and exclusion criteria. Tumor-to-brain uptake ratio (TBR) and metabolic tumor volumes were assessed for diagnostic performances (newly diagnosed, 15; previously treated 26), change with therapy (newly diagnosed, 9; previously treated 7), and variability among different histology ( = 12) and molecular markers ( = 7) of pLGGs.
The sensitivity of [C]-MET-PET for diagnosing pLGG, newly diagnosed, and previously treated combined was 93% for both TBR and TBR, 76% for TBR, and 95% for qualitative evaluation. TBR showed a statistically significant reduction after treatment, while other PET parameters showed a tendency to decrease. Median TBR, TBR, and TBR values were slightly higher in the BRAFV600E mutated tumors compared to the BRAF fused tumors. Median TBR, and TBR in diffuse astrocytomas were higher compared to pilocytic astrocytomas, but median TBR, was slightly higher in pilocytic astrocytomas. However, formal statistical analysis was not done due to the small sample size.
Our study shows that [C]-MET-PET reliably characterizes new and previously treated pLGGs. Our study also shows that quantitative parameters tend to decrease with treatment, and differences may exist between various pLGG types.
[碳]-蛋氨酸正电子发射断层扫描(PET;[碳]-MET-PET)主要用于评估成人脑肿瘤。尽管氨基酸PET示踪剂在儿科脑肿瘤评估中更常用,但关于儿科低级别胶质瘤(pLGG)的[碳]-MET-PET成像数据稀缺。本研究旨在探讨[碳]-MET-PET在pLGG评估中的作用。
18例新诊断的pLGG患者和26例既往接受过治疗的pLGG患者接受了符合纳入和排除标准的[碳]-MET-PET检查。评估肿瘤与脑摄取比(TBR)和代谢肿瘤体积,以分析其在诊断(新诊断的15例、既往接受过治疗的26例)、治疗反应(新诊断的9例、既往接受过治疗的7例)以及不同组织学类型(n = 12)和分子标志物(n = 7)的pLGG之间的变异性。
[碳]-MET-PET诊断pLGG(新诊断与既往接受过治疗的患者合并)时,TBR和代谢肿瘤体积的敏感性均为93%,TBR为76%,定性评估为95%。治疗后TBR有统计学显著降低,而其他PET参数有下降趋势。BRAFV600E突变型肿瘤的TBR、代谢肿瘤体积和TBR中位数略高于BRAF融合型肿瘤。弥漫性星形细胞瘤的TBR和代谢肿瘤体积中位数高于毛细胞型星形细胞瘤,但毛细胞型星形细胞瘤的TBR中位数略高。然而,由于样本量小未进行正式的统计学分析。
我们的研究表明,[碳]-MET-PET能可靠地表征新诊断和既往接受过治疗的pLGG。我们的研究还表明,定量参数往往随治疗而降低,不同类型的pLGG之间可能存在差异。